Annual Review of Cancer Biology

Papers
(The median citation count of Annual Review of Cancer Biology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Immune Cell Metabolism and Immuno-Oncology93
YAP, TAZ, and Hippo-Dysregulating Fusion Proteins in Cancer63
Advances in Therapies Targeting Inhibitory Checkpoint Receptors: TIGIT, LAG-3, and Beyond33
lncRNAs as Targetable Nodes of Oncogenic Networks Underlying Cancer Progression and Therapy Resistance31
Distinct Essentiality of the Mitochondrial Respiratory Chain in Proliferating Cells In Vivo31
Targeting Solid Tumors with Bispecific T Cell Engager Immune Therapy30
Mitochondria, OXPHOS, and Cancer Progression: A Modular View28
Lessons from 3D Reconstruction of Cancer28
Natural and Engineered Cytokines as Cancer Therapeutics27
Allogeneic CAR T Cell Therapy for Cancer26
They Contain Multitudes: The Diverse Roles of CD4+ T Cells in Cancer Immunity26
Cancer Genomic Rearrangements and Copy Number Alterations from Errors in Cell Division25
Beyond Mice and Men: Alternative Vertebrate and Invertebrate Models in Cancer Biology23
Therapeutic Discovery for Chromatin Complexes: Where Do We Stand?22
Caught in a Web: Emerging Roles of Neutrophil Extracellular Traps in Cancer20
Road Map to Defeat Pancreatic Cancer19
Stalled CARs: Mechanisms of Resistance to CAR T Cell Therapies19
Cancer Dependency Map: Past and Present17
Gut Microbiota in Colorectal Cancer: Associations, Mechanisms, and Clinical Approaches15
Rationales for Combining Therapies to Treat Cancer: Independent Action, Response Correlation, and Collateral Sensitivity Versus Synergy13
Engineering Cancer with Next-Generation Genome Editing Tools13
An Erratic Path Toward Discovery12
The Effects of Clonal Heterogeneity on Cancer Immunosurveillance12
Targeting RAS for Cancer Treatment: What a Long, Strange Trip It's Been12
Glycosylation in Cancer: From Functional Roles to Therapeutic Implications11
Reinventing Radiobiology in the Light of FLASH Radiotherapy11
Engineering the Immune Microenvironment into Organoid Models11
Strategies for Heating Up Cold Tumors to Boost Immunotherapies11
Extrachromosomal DNA: Biogenesis and Functions in Cancer11
Targeting Minimal Residual Disease11
Antibody–Drug Conjugates: The Past, Present and Future10
RB1, Cancer Lineage Plasticity, and Therapeutic Resistance10
Mechanism of Action of PARP Inhibitors10
Metabolic Rewiring During Metastasis: The Interplay Between the Environment and the Host9
Novel Mouse Models for Cancer Immunology9
Next-Generation Therapies for Multiple Myeloma8
Emerging Mechanisms of Lactate Regulation of Biological Processes8
Not All Carcinogens Are Directly Mutagenic: A Holistic View of the Environmental Exposure–Cancer Connection8
Cancer Dormancy as a Collective Phenomenon Across Scales in Length and Time: Biological Observations and Advanced 3D Bioengineered Models8
8
Metabolic Reprogramming in Cancer Cachexia8
Lineage-Specific Transcription Factors in Carcinogenesis7
Targeting BET Bromodomains in Cancer7
DNA-Encoded Libraries in Cancer Research: Recent Landmarks and Future Promises7
Awakening the Genome: CRISPR Activation to Unravel the Origin and Vulnerabilities of Cancer4
TRACERx as an Optimized Paradigm for Understanding Cancer Evolution3
3
New Tools for Lineage Tracing in Cancer In Vivo3
3
Development of PROTAC Degrader Drugs for Cancer3
Chemical Proteomics–Guided Discovery of Covalent Ligands for Cancer Proteins3
The Metabolic Relationship Between Viral Infection and Cancer3
Germline Predisposition to Hematopoietic Malignancies: An Overview3
Complex Roles of PTPN11/SHP2 in Carcinogenesis and Prospect of Targeting SHP2 in Cancer Therapy3
0.037658929824829